TY - JOUR
T1 - Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs)
T2 - systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs
AU - Gwinnutt, James M
AU - Wieczorek, Maud
AU - Rodríguez-Carrio, Javier
AU - Balanescu, Andra
AU - Bischoff-Ferrari, Heike A
AU - Boonen, Annelies
AU - Cavalli, Giulio
AU - de Souza, Savia
AU - de Thurah, Annette
AU - Dorner, Thomas E
AU - Moe, Rikke Helene
AU - Putrik, Polina
AU - Silva-Fernández, Lucía
AU - Stamm, Tanja
AU - Walker-Bone, Karen
AU - Welling, Joep
AU - Zlatković-Švenda, Mirjana
AU - Guillemin, Francis
AU - Verstappen, Suzanne M M
N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
PY - 2022/6
Y1 - 2022/6
N2 - BACKGROUND: A EULAR taskforce was convened to develop recommendations for lifestyle behaviours in rheumatic and musculoskeletal diseases (RMDs). In this paper, the literature on the effect of diet on the progression of RMDs is reviewed.METHODS: Systematic reviews and meta-analyses were performed of studies related to diet and disease outcomes in seven RMDs: osteoarthritis (OA), rheumatoid arthritis (RA), systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis and gout. In the first phase, existing relevant systematic reviews and meta-analyses, published from 2013 to 2018, were identified. In the second phase, the review was expanded to include published original studies on diet in RMDs, with no restriction on publication date. Systematic reviews or original studies were included if they assessed a dietary exposure in one of the above RMDs, and reported results regarding progression of disease (eg, pain, function, joint damage).RESULTS: In total, 24 systematic reviews and 150 original articles were included. Many dietary exposures have been studied (n=83), although the majority of studies addressed people with OA and RA. Most dietary exposures were assessed by relatively few studies. Exposures that have been assessed by multiple, well conducted studies (eg, OA: vitamin D, chondroitin, glucosamine; RA: omega-3) were classified as moderate evidence of small effects on disease progression.CONCLUSION: The current literature suggests that there is moderate evidence for a small benefit for certain dietary components. High-level evidence of clinically meaningful effect sizes from individual dietary exposures on outcomes in RMDs is missing.
AB - BACKGROUND: A EULAR taskforce was convened to develop recommendations for lifestyle behaviours in rheumatic and musculoskeletal diseases (RMDs). In this paper, the literature on the effect of diet on the progression of RMDs is reviewed.METHODS: Systematic reviews and meta-analyses were performed of studies related to diet and disease outcomes in seven RMDs: osteoarthritis (OA), rheumatoid arthritis (RA), systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis and gout. In the first phase, existing relevant systematic reviews and meta-analyses, published from 2013 to 2018, were identified. In the second phase, the review was expanded to include published original studies on diet in RMDs, with no restriction on publication date. Systematic reviews or original studies were included if they assessed a dietary exposure in one of the above RMDs, and reported results regarding progression of disease (eg, pain, function, joint damage).RESULTS: In total, 24 systematic reviews and 150 original articles were included. Many dietary exposures have been studied (n=83), although the majority of studies addressed people with OA and RA. Most dietary exposures were assessed by relatively few studies. Exposures that have been assessed by multiple, well conducted studies (eg, OA: vitamin D, chondroitin, glucosamine; RA: omega-3) were classified as moderate evidence of small effects on disease progression.CONCLUSION: The current literature suggests that there is moderate evidence for a small benefit for certain dietary components. High-level evidence of clinically meaningful effect sizes from individual dietary exposures on outcomes in RMDs is missing.
KW - Arthritis, Rheumatoid
KW - Diet
KW - Humans
KW - Life Style
KW - Muscular Diseases
KW - Musculoskeletal Diseases/epidemiology
KW - Osteoarthritis/epidemiology
KW - Rheumatic Diseases/epidemiology
KW - VITAMIN-D SUPPLEMENTATION
KW - LUPUS-ERYTHEMATOSUS
KW - RANDOMIZED DOUBLE-BLIND
KW - epidemiology
KW - MEDITERRANEAN-TYPE DIET
KW - arthritis
KW - FISH OIL SUPPLEMENTATION
KW - KNEE OSTEOARTHRITIS DATA
KW - ARTHRITIS PATIENTS
KW - patient reported outcome measures
KW - POLYUNSATURATED FATTY-ACIDS
KW - PLACEBO-CONTROLLED TRIAL
KW - QUALITY-OF-LIFE
U2 - 10.1136/rmdopen-2021-002167
DO - 10.1136/rmdopen-2021-002167
M3 - (Systematic) Review article
C2 - 35654458
SN - 2056-5933
VL - 8
JO - RMD Open
JF - RMD Open
IS - 2
M1 - e002167
ER -